title: Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography.
abstract: OBJECTIVE
  To assess the efficacy of (1)H MR spectroscopy (MRS) to evaluate early responses to neoadjuvant chemotherapy in breast cancer patients, as compared to that of the standardized uptake value (SUV) in (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET).
  
  
  METHODS
  This retrospective study included seven patients with breast cancer who had both single-voxel (1)H MRS and PET/computed tomography (CT) acquired before, during, and after neoadjuvant chemotherapy.
  
  
  RESULTS
  The averages of the Choline (Cho) integral value and peak SUV before chemotherapy were 2.5 (range, 1.2-5.3) and 7.5 (range, 1.9-19), respectively. Three cases became negative for both Cho and peak SUV after two cycles of chemotherapy, and one patient became negative before surgery. In the remaining three patients, the curves of both values paralleled the time course of chemotherapy treatment. The difference between Cho and peak SUV before, during, and after chemotherapy was r = 0.65 (P = 0.12), r = 0.80 (P = 0.03), and r = 0.99 (P < 0.001), respectively. The reduction rate (RR) of both values after chemotherapy was also correlated (r = 0.84, P = 0.02).
  
  
  CONCLUSIONS
  A change in the Cho integral value is well correlated with that of peak SUV in the time course of neoadjuvant chemotherapy; thus, breast (1)H MRS is thought to be an alternative to sequential (18)F-FDG PET.
authors.affiliation: Breast Center, Kameda Medical Center, Chiba, Japan. e-tozaki@keh.biglobe.ne.jp
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Tozaki
authors.forename: Masaaki
authors.initials: M
authors.lastname: Sakamoto
authors.forename: Yu
authors.initials: Y
authors.lastname: Oyama
authors.forename: Toshihiro
authors.initials: T
authors.lastname: O'uchi
authors.forename: Naoko
authors.initials: N
authors.lastname: Kawano
authors.forename: Takako
authors.initials: T
authors.lastname: Suzuki
authors.forename: Norie
authors.initials: N
authors.lastname: Yamashiro
authors.forename: Shinji
authors.initials: S
authors.lastname: Ozaki
authors.forename: Naomi
authors.initials: N
authors.lastname: Sakamoto
authors.forename: Kuniki
authors.initials: K
authors.lastname: Higa
authors.forename: Satoko
authors.initials: S
authors.lastname: Abe
authors.forename: Tomoko
authors.initials: T
authors.lastname: Ogawa
authors.forename: Eisuke
authors.initials: E
authors.lastname: Fukuma
mesh_terms: D000328:Adult; D000465:Algorithms; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D002794:Choline / Q000378:metabolism; D003287:Contrast Media / Q000493:pharmacokinetics; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D019786:Gadolinium DTPA / Q000493:pharmacokinetics; D006801:Humans; D007091:Image Processing, Computer-Assisted; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012189:Retrospective Studies; D014055:Tomography, Emission-Computed / Q000379:methods; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D019786:Gadolinium DTPA; D002794:Choline